Orphit

Science de la vie

  • Entrée à l’incubateur :
  • Laboratoire(s) associé(s) :Laboratoire INSERM-Univ Montpellier U1198, équipe MMDN

site internet

Le projet

ORPHIT is committed to advancing clinical development of YMALZEN, a peptide that combines anti-inflammatory and neuroprotective properties, as a treatment for Alzheimer’s disease.
With an innovative clinical development supported by international key opinion leaders and based on the use of biomarkers and brain imaging techniques, ORPHIT aims at achieving proof of efficacy for YMALZEN in Alzheimer patients by 2020.

Orphit

  • Créée le

site internet

ORPHIT is committed to advancing clinical development of YMALZEN, a peptide that combines anti-inflammatory and neuroprotective properties, as a treatment for Alzheimer’s disease.
With an innovative clinical development supported by international key opinion leaders and based on the use of biomarkers and brain imaging techniques, ORPHIT aims at achieving proof of efficacy for YMALZEN in Alzheimer patients by 2020.